Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma (OPTIMUM)

This study has been completed.
Information provided by:
Celgene Identifier:
First received: March 23, 2007
Last updated: March 27, 2013
Last verified: September 2009
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2009
  Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):